Savara Inc
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI, an investigational inhaled biologic being developed to treat autoimmune pulmonary alveolar proteinosis. The drug is administered once daily through a proprietary eFlow Nebulizer System. The FDA formally filed Savara’s biologics license application for MOLBREEVI in February 2026 and granted Priority Review. Savara also runs an expanded access program for eligible patients in select countries. Savara holds global rights to MOLBREEVI and plans to commercialize it following regulatory approval, potentially with strategic partners. It outsources most clinical development and manufacturing, using contract manufacturers and service providers rather than operating its own manufacturing facilities. Savara is headquartered in Austin, Texas.
No SEC Form 4 filings for $SVRA in the last 30 days.
See all $SVRA insider activity →Savara Inc. (SVRA) will report Q3 earnings on Nov. 16, ahead of an FDA decision on Nov. 22 for its experimental lung disease treatment, MOLBREEVI. Analysts expect a loss of 15.5 cents per share and zero revenue. All nine analysts rate it a buy, with a consensus price target of $11.06. The company's cash position and launch planning will be key focuses. Savara operates at a loss, with Q2 results missing expectations.
Savara Inc. (SVRA) reported improvements in lung function and imaging measures in a small subgroup of patients with autoimmune pulmonary alveolar proteinosis (aPAP) treated with molgramostim, according to a retrospective analysis presented at CHEST 2026. The analysis included 11 patients and showed a 12.7 mmHg improvement in the alveolar-arterial oxygen gradient for molgramostim recipients compared to 0.3 mmHg for placebo. The company noted the findings are exploratory and not definitive.
Savara Inc. (SVRA) presented data from the IMPALA trial at CHEST 2026, showing improved oxygen transfer in 7 patients treated with molgramostim. The drug reduced A–aDO₂ by 12.7 mmHg vs. -0.3 mmHg for placebo. Respiratory quality of life and surfactant burden also improved. Results are exploratory due to small sample size.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SVRA (Savara Inc). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent SVRA coverage spans financial news, corporate actions and earnings.
Earnings preview and pending FDA ruling create near‑term volatility; a miss could pressure the stock, while positive guidance or approval could spark upside.
Exploratory data may boost investor optimism but limited by small sample size.
Positive early‑stage signal may lift sentiment toward Savara’s molgramostim program.
Analyst upgrade and high price target could attract buying interest, especially if FDA approval occurs.
Overweight rating may lift the biotech.
AlphAI scores every news story that mentions SVRA with an AI model for sentiment and relevance, and aggregates insider trades from Savara Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Savara Inc. (SVRA) will report Q3 earnings on Nov. 16, ahead of an FDA decision on Nov. 22 for its experimental lung disease treatment, MOLBREEVI. Analysts expect a loss of 15.5 cents per share and zero revenue. All nine analysts rate it a buy, with a consensus price target of $11.06. The company's cash position and launch planning will be key focuses. Savara operates at a loss, with Q2 results missing expectations.
Savara Inc. (SVRA) reported improvements in lung function and imaging measures in a small subgroup of patients with autoimmune pulmonary alveolar proteinosis (aPAP) treated with molgramostim, according to a retrospective analysis presented at CHEST 2026. The analysis included 11 patients and showed a 12.7 mmHg improvement in the alveolar-arterial oxygen gradient for molgramostim recipients compared to 0.3 mmHg for placebo. The company noted the findings are exploratory and not definitive.
Savara Inc. (SVRA) presented data from the IMPALA trial at CHEST 2026, showing improved oxygen transfer in 7 patients treated with molgramostim. The drug reduced A–aDO₂ by 12.7 mmHg vs. -0.3 mmHg for placebo. Respiratory quality of life and surfactant burden also improved. Results are exploratory due to small sample size.
JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and a $12 price target, implying 146% upside from its $4.88 close. The stock has fallen 30% since December, with FDA delays and wider losses. Analysts expect approval of Molbreevi on Nov. 22 to drive the stock's performance, with sales projections starting at $2.02M this year.
Analysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.
Citizens reiterated a Market Outperform rating and $10.00 price target for Savara (SVRA), citing a 90% approval probability for Molbreevi. The firm expects strong launch prospects and undervaluation, with a peak sales potential implying a $1.6B-$2.0B valuation. SVRA shares are at $4.65, up 35.6% over the past year.
The FDA’s August 2026 Prescription Drug User Fee Act calendar includes target action dates for multiple investigational drugs and therapies. Moderna’s mRNA-1010 has an Aug 5, 2026 PDUFA date. Gilead’s bictegravir/lenacapavir has Aug 27. Lantheus’ MK-6240 has Aug 13. Other listed PDUFA dates cover programs from Capricor, BMS, Jazz, Savara, Ultragenyx, PharmaEssentia, Regeneron, Takeda, and Priovant.
Savara Inc. (Nasdaq: SVRA) said the European Patent Office granted a patent for the liquid formulation of MOLBREEVI, covering protection in Europe through March 2041 (EP No. 4121000). It also said Australia’s patent office granted a related patent (No. 62/990,810) through March 2041. MOLBREEVI is in Phase 3 for autoimmune PAP.
Lowrance David L (Chief Financial Officer) sold 394,528 shares of Savara Inc (SVRA) at $5.68 ($2.24M total) on 2026-06-22.
Savara Inc (SVRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K Savara Inc false 0001160308 --12-31 0001160308 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event rep
